Uterine leiomyosarcoma with central nervous system metastases

Area of Science:

• Gynecologic Oncology
• Surgical Oncology
• Medical Oncology

Background:

• Uterine leiomyosarcoma (LMS) is a rare malignancy, accounting for 2-3% of uterine cancers.
• LMS exhibits aggressive behavior, high recurrence rates, and poor survival outcomes despite treatment.
• Total abdominal hysterectomy is the primary surgical intervention.

Observation:

• Adjuvant radiotherapy has demonstrated improved locoregional control in early-stage (I and II) uterine sarcomas.
• The efficacy of adjuvant chemotherapy for LMS remains uncertain.
• Approximately 50% of patients with organ-confined LMS develop distant metastases.

Findings:

• Adjuvant radiotherapy improves locoregional control in early-stage uterine sarcomas.
• The role of adjuvant chemotherapy in LMS treatment is still under investigation.
• Distant metastases commonly affect the lungs, peritoneum, liver, and lymph nodes, with brain involvement being rare.

Implications:

• Optimizing adjuvant treatment strategies is crucial for improving outcomes in uterine leiomyosarcoma.
• Further research is needed to clarify the role of chemotherapy in LMS management.
• Understanding common metastatic patterns can guide surveillance and treatment decisions for LMS patients.